Taxotere, Docetaxel Newswire (Page 5)

Taxotere, Docetaxel Newswire (Page 5)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 5)

Results 81 - 100 of 396 in Taxotere, Docetaxel (generic)

  1. Eagle Pharmaceuticals Inc. (EGRX) Stock Rating Lowered by MizuhoRead the original story w/Photo

    Nov 17, 2016 | Daily Political

    They presently have a $78.00 target price on the specialty pharmaceutical company's stock. Mizuho's price target suggests a potential downside of 0.23% from the company's current price.

    Comment?

  2. One CEO's Push to Make Cancer Drugs and Condoms Great AgainRead the original story

    Nov 17, 2016 | The Washington Post

    Fairley's biotechnology company, Starpharma Holdings Ltd., holds dozens of patents for ways to make medicines perform better. The Australian firm capitalized on one application of that technology by creating a gel to coat condoms to improve protection against sexually transmitted diseases and the spread of viruses like Zika through sex.

    Comment?

  3. Mizuho Downgrades Eagle Pharmaceuticals Inc. (EGRX) to NeutralRead the original story w/Photo

    Nov 16, 2016 | AmericanBankingNews.com

    They presently have a $78.00 price target on the specialty pharmaceutical company's stock. Mizuho's price target points to a potential upside of 2.94% from the company's previous close.

    Comment?

  4. Easton Pharmaceuticals Announces Receipt Of All Technical Documents...Read the original story

    Nov 15, 2016 | BioSpace

    Easton Pharmaceuticals Inc. announces that all required technical documents have been received from Biolyse Pharma Corporation of St. Catharines, Ontario, Canada, for cancer drug Paclitaxel and are now ready for submission for fast track approval with the Mexican Ministry Of Health. Easton Pharmaceuticals and partner BMV Medica have secured the rights from Biolyse Pharma to distribute the generic cancer drugs Docetaxel and Paclitaxel for Mexico and Latin America.

    Comment?

  5. Role of genetic variation in docetaxel-induced neutropenia and pharmacokineticsRead the original story

    Nov 16, 2016 | The Pharmacogenomics Journal

    Correspondence: Dr RHN van Schaik, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam 3015CE, The Netherlands. E-mail: [email protected] Docetaxel is used for treatment of several solid malignancies.

    Comment?

  6. Easton Pharmaceuticals Announces Receipt of all Technical Documents...Read the original story w/Photo

    Nov 15, 2016 | Market Wire

    Easton Pharmaceuticals and partner BMV Medica have secured the rights from Biolyse Pharma to distribute the generic cancer drugs Docetaxel and Paclitaxel for Mexico and Latin America. The regulatory landscape and requirements have recently changed regarding the validation and sourcing of raw materials or Active Pharmaceutical Ingredients received for incorporation into the final manufacturing process from overseas suppliers, which has caused delays in the filing process.

    Comment?

  7. OncoGenex Reports Financial Results For Third Quarter 2016Read the original story

    Nov 13, 2016 | BioSpace

    The company does not currently intend to fund further development of apatorsen in bladder cancer without a collaboration partner. , OncoGenex discontinued the development of its custirsen program after the AFFINITY and ENSPIRIT Phase 3 clinical trials failed to meet their primary endpoints.

    Comment?

  8. Eagle Pharmaceuticals Inc. (EGRX) Receives Consensus Rating of "Buy" from BrokeragesRead the original story w/Photo

    Nov 14, 2016 | Daily Political

    Shares of Eagle Pharmaceuticals Inc. have been assigned an average rating of "Buy" from the eight ratings firms that are currently covering the firm. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company.

    Comment?

  9. FY2018 Earnings Estimate for Eagle Pharmaceuticals Inc. (EGRX) Issued By William BlairRead the original story w/Photo

    Nov 11, 2016 | AmericanBankingNews.com

    Eagle Pharmaceuticals Inc. - Equities researchers at William Blair cut their FY2018 earnings per share estimates for shares of Eagle Pharmaceuticals in a research note issued to investors on Wednesday. William Blair analyst T. Lugo now forecasts that the firm will post earnings of $5.64 per share for the year, down from their previous forecast of $5.82.

    Comment?

  10. FDA Expands Opdivo Indications to Include Head-and-Neck CancerRead the original story

    Nov 11, 2016 | P&T Community

    The FDA has given the nod to nivolumab for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy. Nivolumab is the only immuno-oncology treatment shown in a phase 3 trial to significantly extend overall survival for these patients.

    Comment?

  11. Eagle Pharmaceuticals Inc. (EGRX) Lifted to Buy at Zacks Investment ResearchRead the original story w/Photo

    Nov 10, 2016 | Daily Political

    They currently have $84.00 target price on the specialty pharmaceutical company's stock. According to Zacks, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company.

    Comment?

  12. TGen's Dr. Von Hoff is named a 'Giant of Cancer Care'Read the original story w/Photo

    Nov 9, 2016 | EurekAlert!

    Nov. 10, 2016 -- Dr. Daniel Von Hoff, Physician-In-Chief and Distinguished Professor at the Translational Genomics Research Institute , has been selected as a 2016 Giant of Cancer Care. Dr. Von Hoff, a world-renowned expert in pancreatic cancer, was honored for his work in the field of gastrointestinal cancer.

    Comment?

  13. Expensive chemotherapy 'does little to boost survival in advanced cancer cases'Read the original story w/Photo

    Nov 10, 2016 | Sunday Herald

    Expensive chemotherapy does little to improve survival for people with advanced cancer, who often have "unrealistic expectations", an expert has said. Peter Wise, a former consultant physician at Charing Cross Hospital in London, said spending "six figure" sums on chemotherapy drugs is inappropriate for many people with advanced cancer who will "almost inevitably die" from their tumours.

    Comment?

  14. A consultant has warned about the benefits of chemotherapy being overestimated.Read the original story w/Photo

    Nov 9, 2016 | This is Local London

    Expensive chemotherapy does little to improve survival for people with advanced cancer, who often have "unrealistic expectations", an expert has said. Peter Wise, a former consultant physician at Charing Cross Hospital in London, said spending "six figure" sums on chemotherapy drugs is inappropriate for many people with advanced cancer who will "almost inevitably die" from their tumours.

    Comment?

  15. Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 ResultsRead the original story

    Nov 9, 2016 | Customer Interaction Solutions

    Eagle Pharmaceuticals, Inc. today announced its financial results for the three- and nine-months ended September 30, 2016. Highlights of and subsequent to the third quarter of 2016 include: Positive initial results of animal study exploring use of Ryanodex in MDMA induced hyperthermia conducted at the National Institutes of Health ; Extended our licensing agreement with Teva Pharmaceutical Industries Ltd. to include certain territories outside the US and Canada; and Repurchased $18.0 million of Eagle common stock during the third quarter for a total of $32.0 million since commencing the Share Repurchase Program on August 9, 2016.

    Comment?

  16. Eagle Pharmaceuticals Inc. (EGRX) to Release Quarterly Earnings on WednesdayRead the original story

    Nov 8, 2016 | AmericanBankingNews.com

    Eagle Pharmaceuticals Inc. is set to announce its Q316 earnings results on Wednesday, November 9th. Analysts expect the company to announce earnings of $0.75 per share and revenue of $41.04 million for the quarter.

    Comment?

  17. Easton Pharmaceuticals Announces Receipt Of Preliminary Proposal From ...Read the original story

    Nov 6, 2016 | BioSpace

    Easton Pharmaceuticals Inc. and partner BMV Medica SA have received a preliminary proposal from a major multi-national pharmaceutical company for its regulatory approved, patented VagiSan woman's diagnostic test Bacterial Vaginosis for Mexico and Ecuador. Negotiations with a second major pharmaceutical company for other Easton/BMV products has moved to contract phase.

    Comment?

  18. New KEYTRUDA (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual MeetingRead the original story w/Photo

    Nov 7, 2016 | Freshnews

    Merck , known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDAA , the company's anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer's 31st Annual Meeting, Nov. 9-13. Data on overall survival and progression-free survival from the phase 3 KEYNOTE-045 study - investigating KEYTRUDA compared to investigator's choice chemotherapy in patients with metastatic or locally advanced or unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy - will be presented for the first time; these data were accepted as a late-breaking abstract.

    Comment?

  19. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits ...Read the original story

    Nov 7, 2016 | Prostate Cancer and Prostatic Diseases

    Correspondence: Dr S Gupta, GU Medical Oncology, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Ste 2163, Salt Lake City, UT 84112, USA. E-mail: [email protected] Lysine-specific demethylase 1 overexpression correlates with poor survival and castration resistance in prostate cancer.

    Comment?

  20. Eagle Pharmaceuticals Inc. (EGRX) Price Target Increased to $93.00 by ...Read the original story w/Photo

    Nov 6, 2016 | AmericanBankingNews.com

    The firm currently has an "outperform" rating on the specialty pharmaceutical company's stock. Royal Bank Of Canada's price target indicates a potential upside of 24.07% from the company's previous close.

    Comment?